Maria Svensson, MD, Lund University, discusses the impact of determining PD-L1 status for patients with esophageal and gastric adenocarcinoma.

In a study of patients with resectable esophageal and gastric cancer, investigators sought to examine the expression of PD-L1 in tumor cells and tumor-infiltrating immune cells, and the PD-1 receptor as it relates to mismatch repair (MMR) status.

It is important to find good biomarkers for prognosis, explains Svensson. Patients with high PD-L1 expression in tumor-infiltrating lymphocytes (TILs) had prolonged survival. In this study, the prognostic value was evident in MMR-proficient tumors. PD-L1 expression and MMR status can be useful in the clinic in the future for different settings, adds Svensson.

Videos

Maria Svensson, MD, Lund University, discusses the impact of determining PD-1 and PD-L1 status for patients with esophageal and gastric adenocarcinoma.

Dr. Svensson on the Impact of PD-L1 Status in Gastric and Esophageal Adenocarcinoma

Maria Svensson, MD, Lund University, discusses the associations of PD-1 and PD-L1 expression with mismatch repair (MMR) status and prognosis in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.

In a study of patients with resectable esophageal and gastric cancer, investigators sought to examine the expression of PD-L1 in tumor cells and tumor-infiltrating immune cells, and the receptor PD-1 as it relates to MMR status.

Results showed that PD-1 expression was not associated with MMR status, Svensson says. Although, the expression of PD-L1 in both tumor cells and tumor-infiltrating immune cells was significantly associated with MMR deficiency (

 < .001 for both). Neither PD-L1 expression or MMR status in tumor cells was prognostic, whereas high PD-1 expression (10%) in tumor infiltrating immune cells was associated with prolonged overall survival (

View more from the 2018 GI Cancer Symposium

Maria Svensson, MD

Articles

Dr. Svensson on the Impact of PD-L1 Status in Gastric and Esophageal Adenocarcinoma

Dr. Svensson on PD-1/PD-L1 Status in Esophageal and Gastric Adenocarcinoma